CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
Ipilimumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02833233
NCT02833233N/ACompleted
CompareCT.gov

A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Jul 14, 2016·Updated Oct 23, 2024

In Brief

A clinical study evaluating Cryoablation, Ipilimumab, and 1 other intervention for Breast Cancer. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This study is being done to evaluate the safety of combining two strategies called "cryoablation" and "immune therapy" in women with curable early stage breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 14, 2016
Enrollment StartJun 1, 2016
Primary CompletionJun 7, 2024
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 10.0 years ago

Interventions

Cryoablationprocedure

Ipilimumabdrug

Nivolumabdrug